TIBSOVO (ivosidenib tablets) was studied in a patient population reflective of that seen in clinical practice

Selected baseline demographic and disease characteristics (N=174)1
Median age, years (min, max) 67 (18, 87)
ECOG PS
0 36 (21)
1 97 (56)
2 39 (22)
3 2 (1)
IDH1 mutation
R132C 102 (59)
R132H 43 (25)
R132G 12 (7)
R132S 10 (6)
R132L 7 (4)
Cytogenetic risk status
Intermediate 104 (60)
Poor 47 (27)
Missing/unknown 23 (13)
Relapse type
Primary refractory 64 (37)
Refractory relapse 45 (26)
Untreated relapse 65 (37)
Prior stem cell transplantation for AML 40 (23)
Transfusion dependent at baselinea 110 (63)
Type of AML
De novo AML 116 (67)
Secondary AML 58 (33)

aPatients were defined as transfusion dependent at baseline if they received any RBC or platelet transfusion occurring within 56 days prior to the first dose of TIBSOVO.1

Many patients in the study had challenging disease characteristics

63 Chart

59% of patients had ≥2 prior anticancer therapies2

  • Median number of prior therapies (min, max): 2 (1, 6)1

33% of patients had secondary AML1

23% of patients had prior stem cell transplantation for AML1

87% of patients had intermediate or poor cytogenic risk status1

Study design

TIBSOVO® was studied as a single agent in both the newly diagnosed and R/R AML settings1

TIBSOVO is a first-in-class agent that inhibits the mutant IDH1 enzyme to induce myeloid differentiation1

  • The pivotal trial for TIBSOVO monotherapy was an open-label, single-arm, multicenter trial1
  • IDH1 mutations were identified by a local or central diagnostic test and confirmed retrospectively using the Abbott RealTime IDH1 assay, which is the FDA-approved test for selection of patients with AML for treatment with TIBSOVO1
Patients were assigned a starting dose of TIBSOVO 500 mg daily and received treatment until disease progression, development of unacceptable toxicity, or undergoing hematopoietic stem cell transplantation1
  • Safety and efficacy were evaluated in 28 IC-ineligible patients with newly diagnosed AML1
  • Safety was evaluated in 179 patients and efficacy was evaluated in 174 patients with R/R AML1

Efficacy was established based on the rate of CR and/or CRh, duration of CR+CRh, as well as the rate of conversion from transfusion dependence to transfusion independence1,a

aCR was defined as <5% blasts in the bone marrow and no Auer rods, absence of extramedullary disease, full recovery of peripheral blood counts (absolute neutrophil count >1000/μL and platelets >100,000/μL), and independence of red blood cell transfusions.2 CRh was defined as <5% blasts in the bone marrow and no Auer rods, absence of extramedullary disease, and partial recovery of peripheral blood counts (absolute neutrophil count >500/μL and platelets >50,000/μL).1
AML, acute myeloid leukemia; CR, complete remission; CRh, complete remission with partial hematological recovery; IC, induction chemotherapy; IDH1, isocitrate dehydrogenase-1; R/R, relapsed or refractory.

AML, acute myeloid leukemia; ECOG PS, Eastern Cooperative Oncology Group Performance Status; IDH1, isocitrate dehydrogenase‑1; RBC, red blood cell.

TIBSOVO delivered deep responses as a once-daily oral treatment in a difficult-to-treat disease

33 Chart 33 Chart
  • CR+CRh rate appeared to be consistent across all baseline demographics and baseline disease characteristics with the exception of number of prior regimens1

bCR was defined as <5% blasts in the bone marrow and no Auer rods, absence of extramedullary disease, full recovery of peripheral blood counts (absolute neutrophil count >1000/μL and platelets >100,000/μL), and independence of red blood cell transfusions.1,2 CRh was defined as <5% blasts in the bone marrow and no Auer rods, absence of extramedullary disease, and partial recovery of peripheral blood counts (absolute neutrophil count >500/μL and platelets >50,000/μL).


Patients achieved CR or CRh after receiving 1 or more prior regimens2

47 Circle

47% of R/R patients who had received 1 prior regimen (35/74) achieved CR or CRh (95% CI, 35.6‑59.3)2

30 Circle

30% of R/R patients who had received 2 prior regimens (15/50) achieved CR or CRh (95% CI, 17.9‑44.6)2

15 Circle

15% of R/R patients who had received ≥3 prior regimens (7/48) achieved CR or CRh (95% CI, 6.1-27.8)2

AML, acute myeloid leukemia; CR, complete remission; CRh, complete remission with partial hematological recovery; R/R, relapsed/refractory.

TIBSOVO provided durable responses1

Median duration of response1,c

Median Duration of Response Chart Median Duration of Response Chart

Description

Horizontal bar chart presenting median duration of response in patients treated with TIBSOVO, reported for complete remission (CR) and composite remission (CR+CRh).

Median duration of response was 10.1 months (95% CI, 6.5–22.2) in patients achieving CR (n=43) and 8.2 months (95% CI, 5.6–12) in patients achieving CR+CRh (n=57).

cDuration of CR and CR+CRh were defined as time since first response of CR or CR/CRh, respectively, to relapse or death, whichever was earlier.1

36% of patients who achieved CR or CRh were in remission at 12 months after initiating treatment2
  • Median treatment duration: 4.1 months (range, 0.1-39.5)1
    • Some patients experienced long treatment durations of over 3 years with TIBSOVO (range, 0.2-39.5 months)1
  • Median follow-up: 8.3 months (range, 0.2-39.5)1

CR, complete remission; CRh, complete remission with partial hematological recovery.

TIBSOVO enabled strong and rapid responses1,3

Time to response with TIBSOVO

Time to Response in Patients Who Achieved CR of CRh Chart Time to Response in Patients Who Achieved CR of CRh Chart
For patients without disease progression or unacceptable toxicity, treat for a minimum of 6 months to allow time for clinical response1

CR, complete remission; CRh, complete remission with partial hematological recovery.

Transfusion independence was seen in 37% of transfusion-dependent patients who received TIBSOVO1

37-transfusion-chart Chart 37-transfusion-chart Chart
59% of patients who were transfusion independent at baseline (38/64) remained so1

Patients were defined as transfusion dependent at baseline if they received any RBC or platelet transfusions within 56 days prior to the first dose of TIBSOVO. Patients were defined as transfusion independent if they became independent of transfusions during any 56-consecutive-day postbaseline period.1

RBC, red blood cell.

TIBSOVO improved hematologic parameters3

TIBSOVO demonstrated an improvement in hematologic variables together with a reduction in bone marrow blasts

Increase in mean platelet count and mean absolute neutrophil counts

Increase in Mean Platelet and Neutrophil Count Graph Increase in Mean Platelet and Neutrophil Count Graph

Description

Line graph presenting the increase in mean platelet count (109/L, left y-axis) and mean absolute neutrophil count (109/L, right y-axis) in patients treated with TIBSOVO monotherapy, measured at each cycle from Cycle 0 through Cycle 12. Error bars are displayed at each timepoint.

Mean platelet counts rise from baseline through Cycle 2, decline through Cycle 3, then increase gradually through Cycle 9, after which values stabilize through Cycle 12. Mean absolute neutrophil counts remain low at baseline, then rise from Cycle 1 onward, increasing gradually through Cycle 12.


Increase in mean hemoglobin level, decrease in mean bone marrow blasts

Increase in Mean Hemoglobin and Decrease in Bone Marrow Blasts Graph Increase in Mean Hemoglobin and Decrease in Bone Marrow Blasts Graph

Description

Line graph presenting the increase in mean hemoglobin level (g/L, left y-axis) and decrease in mean bone marrow blasts (%, right y-axis) in patients treated with TIBSOVO monotherapy, measured at each cycle from Cycle 0 through Cycle 12. Error bars are displayed at each timepoint. The number of patients evaluated at each cycle is noted below the x-axis for both hemoglobin and bone marrow blasts.

Mean hemoglobin levels remain relatively stable from baseline through Cycle 3, then increase gradually through Cycle 12. Mean bone marrow blast percentage declines from baseline through Cycle 4, after which values stabilize and remain relatively consistent through Cycle 12.

Adapted with permission from DiNardo et al.

Data are mean values with standard deviations.

12% of patients (21/174) went on to receive a stem cell transplant following treatment with TIBSOVO1

References: 1. Tibsovo. Package insert. Servier Pharmaceuticals LLC; 2023. 2. Data on file. Servier Pharmaceuticals LLC. 3. DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386-2398. doi:10.1056/NEJMoa1716984

 

INDICATIONS

TIBSOVO is indicated for patients with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test with:

Newly Diagnosed Acute Myeloid Leukemia (AML)

  • In combination with azacitidine or as monotherapy for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy
Indications & Important Safety Information

IMPORTANT SAFETY INFORMATION

WARNING: DIFFERENTIATION SYNDROME IN AML

Patients treated with TIBSOVO have experienced symptoms of differentiation syndrome, which can be fatal. Symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, hypotension, and hepatic, renal, or multi-organ dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution.